Perspective Therapeutics近日宣布，在其两项正在进行的1/2a期临床研究中，新设队列的首批患者已成功接受给药。这一进展标志着公司基于放射性药物的精准肿瘤治疗项目又向前迈出了重要一步。新队列的启动旨在进一步评估其候选疗法的安全性与初步疗效，为后续更大规模的临床开发提供关键数据支持。公司致力于通过创新疗法解决未满足的医疗需求，此次进展有望加速其研发管线的推进。
Perspective Therapeutics近日宣布，在其两项正在进行的1/2a期临床研究中，新设队列的首批患者已成功接受给药。这一进展标志着公司基于放射性药物的精准肿瘤治疗项目又向前迈出了重要一步。新队列的启动旨在进一步评估其候选疗法的安全性与初步疗效，为后续更大规模的临床开发提供关键数据支持。公司致力于通过创新疗法解决未满足的医疗需求，此次进展有望加速其研发管线的推进。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.